- NeuroSense received grant of Brazilian Patent No. BR 112024007727-6 covering PrimeC composition.
- Patent protection in Brazil runs through October 2042.
- Grant follows prior patents in U.S. (12,097,185) and Australia (2022370513).
- Coverage supports PrimeC development in ALS, including planned Phase 3 PARAGON trial.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Neurosense Therapeutics Ltd. published the original content used to generate this news brief via PR Newswire (Ref. ID: 202604060920PR_NEWS_USPR_____LN27382) on April 06, 2026, and is solely responsible for the information contained therein.
Comments